Published in Stat Med on October 09, 2013
Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol (2016) 1.21
Words of wisdom. Re: Modeling grade progression in an active surveillance study. Eur Urol (2014) 0.75
Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. Eur Urol (2017) 0.75
Active Surveillance for Intermediate Risk Prostate Cancer. Curr Urol Rep (2017) 0.75
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol (2009) 10.43
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Bayesian estimation of disease prevalence and the parameters of diagnostic tests in the absence of a gold standard. Am J Epidemiol (1995) 3.39
Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess (2003) 3.25
Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08
Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer (2010) 1.79
Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer (2006) 1.64
Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol (2001) 1.58
Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol (2010) 1.47
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila) (2008) 1.40
Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics (2005) 1.01
PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression. Int J Cancer (2011) 0.98
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care (2002) 4.88
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med (2013) 4.45
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
The effect of shock wave rate on the outcome of shock wave lithotripsy: a meta-analysis. J Urol (2007) 2.78
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol (2011) 2.46
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 2.38
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst (2014) 2.30
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology (2010) 2.27
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Studies of prostate-cancer mortality: caution advised. Lancet Oncol (2008) 2.22
Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol (2011) 2.20
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17
Urinary outcomes are significantly affected by nerve sparing quality during radical prostatectomy. Urology (2013) 2.11
National Institutes of Health state-of-the-science conference statement: prevention of fecal and urinary incontinence in adults. Ann Intern Med (2008) 2.10
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology (2008) 2.04
Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol (2004) 1.95
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med (2014) 1.87
Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol (2004) 1.85
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med (2003) 1.79
Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Sex prevalence of pediatric kidney stone disease in the United States: an epidemiologic investigation. Urology (2009) 1.74
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res (2008) 1.74
Validity of administrative coding in identifying patients with upper urinary tract calculi. J Urol (2010) 1.72
Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol (2007) 1.72
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology (2004) 1.71
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology (2011) 1.71
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol (2005) 1.69
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol (2008) 1.66
Validation of the partin nomogram for prostate cancer in a national sample. J Urol (2010) 1.64
Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol (2008) 1.63
Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance. Urology (2013) 1.63
Laparoscopic live donor nephrectomy: trends in donor and recipient morbidity following 381 consecutive cases. Ann Surg (2004) 1.63
Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology (2003) 1.62
Prostate specific antigen testing among the elderly--when to stop? J Urol (2009) 1.62
Causes of death after radical prostatectomy at a large tertiary center. J Urol (2012) 1.61
Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.60
Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomy. Prostate (2010) 1.60
Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer (2006) 1.60